RAF1 and central nervous system cancer: Knockdown of CAMK2B with siRNA resulted in an increased expression level of Ras, p-Raf, p-MEK, and p-ERK; these effects were inhibited by the Ras inhibitor Salirasib, indicating that Salirasib can inhibit the proliferation of glioma cells both in vivo and in vitro [18,19] (Fig. 6A).